23.58k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change today||1-month return||1-year return||Total return|
|The fight against COVID19||+0.26%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||177.33||+0.09||+0.05%||4:00 pm GMT-5||5.93M||7.03M||463.63B|
|ABBV||AbbVie Inc.||158.43||-1.19||-0.75%||4:03 pm GMT-5||3.74M||5.55M||280.18B|
|PFE||Pfizer Inc.||49.57||+0.36||+0.73%||4:03 pm GMT-5||19.41M||19.88M||278.25B|
|SNY||Sanofi||45.54||+0.15||+0.33%||4:00 pm GMT-5||1.53M||2.83M||115.48B|
|GILD||Gilead Sciences, Inc.||85.21||-1.05||-1.22%||4:00 pm GMT-5||9.25M||8.29M||106.87B|
|REGN||Regeneron Pharmaceuticals, Inc.||741.48||+5.25||+0.71%||4:00 pm GMT-5||531.37k||790.08k||80.75B|
|GSK||GSK plc||33.76||-0.23||-0.68%||4:00 pm GMT-5||5.55M||6.27M||68.66B|
|MRNA||Moderna, Inc.||175.38||-1.02||-0.58%||4:00 pm GMT-5||3.75M||4.89M||67.38B|
|TAK||Takeda Pharmaceutical Company Limited||14.55||-0.03||-0.21%||4:00 pm GMT-5||2.22M||3.06M||45.24B|
|BNTX||BioNTech SE||161.49||+6.64||+4.29%||4:00 pm GMT-5||1.22M||864.01k||39.19B|
|VIR||Vir Biotechnology, Inc.||26.95||-0.28||-1.03%||4:00 pm GMT-5||735.82k||1.02M||3.59B|
|NVAX||Novavax, Inc.||16.64||+0.10||+0.60%||4:00 pm GMT-5||3.41M||4.93M||1.31B|
|INO||Inovio Pharmaceuticals, Inc.||1.9||-0.11||-5.47%||4:00 pm GMT-5||4.90M||5.79M||474.03M|
Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.
In this article, we will discuss the best dividend stocks according to hedge funds with over 5% yield. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best 5% Dividend Stocks To Buy According To Hedge Funds. The current stock market situation has […]
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.